Daiichi Sankyo and Partners Advance Two Major Lung Cancer Trials Targeting KRAS G12C and TROP2-Positive Tumors
核心洞察
Daiichi Sankyo announced updates on two significant lung cancer trials, including a Phase 1b/2 study with Merck (搜索) testing MK-1084 combinations in KRAS G12C (搜索)-mutated non-small cell lung cancer.
The TROPION-Lung17 Phase III trial with AstraZeneca is actively recruiting patients to test datopotamab deruxtecan against docetaxel in TROP2 (搜索)-positive advanced lung cancer without actionable genomic alterations.
Both studies target difficult-to-treat patient populations with high unmet medical needs, potentially expanding treatment options in competitive oncology markets.
Daiichi Sankyo Company announced updates on two pivotal lung cancer clinical trials that could significantly expand treatment options for patients with advanced non-small cell lung cancer (NSCLC). The studies represent strategic partnerships with Merck (搜索) and AstraZeneca, targeting distinct patient populations with high unmet medical needs.
KEYMAKER-U01 Study Tests Novel KRAS G12C Combinations
The KEYMAKER-U01 Substudy 01F represents a Phase 1b/2 umbrella study designed to evaluate investigational agents in previously treated participants with advanced or metastatic nonsquamous NSCLC harboring KRAS G12C (搜索) mutations. This interventional trial tests MK-1084, an oral targeted cancer drug, in combination with three different antibody-based medicines: patritumab deruxtecan (HER3 (搜索)-DXd), sacituzumab tirumotecan (Sac-TMT), and cetuximab.
The study employs a randomized design with dose-escalation followed by parallel treatment groups. Patients first enter a dose-escalation stage where the study team increases doses step by step to find safe levels, after which eligible patients are placed in parallel treatment groups to compare the different combinations. The open-label design allows doctors and patients to know which treatment they receive, with the main purpose focusing on safety and tumor response.
The study was first submitted on November 17, 2025, and received its latest update on December 23, 2025. Currently listed as "Not yet recruiting," patient enrollment is expected to begin following completion of regulatory and site-activation work. Primary and final completion dates have not yet been posted, which is typical for an early-stage, flexible umbrella design that may add or close treatment arms over time.
TROPION-Lung17 Advances to Active Recruitment
The TROPION-Lung17 trial (NCT07291037) represents a Phase III, randomized, open-label, multicentre study comparing datopotamab deruxtecan (Dato-DXd) with docetaxel in previously treated TROP2 (搜索)-positive advanced or metastatic non-squamous NSCLC without actionable genomic alterations. This late-stage study targets patients with advanced non-small cell lung cancer who lack common genetic targets, representing an area with high unmet need.
The experimental treatment, datopotamab deruxtecan, is a targeted antibody-drug conjugate designed to deliver chemotherapy directly to TROP2 (搜索)-positive cancer cells while limiting damage to healthy tissue. The control treatment is docetaxel, a long-standing standard chemotherapy used after other lung cancer therapies stop working. Both drugs are administered by intravenous infusion.
The study employs a sponsor-blind design to limit bias from the companies, with patients randomly assigned to parallel groups. The main aim focuses on treatment outcomes, specifically whether Dato-DXd improves key measures such as progression-free survival and overall survival compared with docetaxel.
First submitted in late October 2025, the trial status was updated to "recruiting" as of December 17, 2025, indicating that patient enrollment is actively under way. Primary completion and final completion dates have not been reported publicly but will likely represent important catalysts once announced.
Market Implications and Competitive Landscape
These updates reinforce the strategic push by Daiichi Sankyo and its partners into competitive lung cancer markets. The KEYMAKER-U01 study positions the companies in the KRAS G12C (搜索) lung cancer space, an area already targeted by players such as Amgen and Mirati/Bristol Myers Squibb. For Daiichi Sankyo, inclusion of its antibody-drug conjugate patritumab deruxtecan as a key partner in this trial strengthens the company's pipeline story in solid tumors beyond breast and gastric cancers.
The TROPION-Lung17 trial represents a key asset in the growing antibody-drug conjugate segment, where both AstraZeneca and Daiichi Sankyo are co-leading through other products. Positive Phase III data in this difficult-to-treat lung cancer setting could support a strong new revenue stream and reinforce their competitive position versus other large players in lung cancer, including Merck (搜索), Bristol Myers Squibb, and Roche.
However, investors should note that the KEYMAKER-U01 study represents a Phase 1b/2 effort at a very early stage, with near-term revenue impact limited and readouts likely several years away. Competitive risk remains high as multiple KRAS G12C (搜索) and antibody-drug conjugate programs are racing to establish best-in-class status. For TROPION-Lung17, while timelines remain long and clinical risk is high, the active recruitment confirms management's commitment to advancing Dato-DXd.
Both trials add incremental pipeline optionality for Daiichi Sankyo and validate its antibody-drug conjugate platform for additional partnerships, potentially supporting premium valuations while providing medium-term catalysts for the company's oncology franchise.